Business Wire

ADVA

30.6.2022 09:02:12 CEST | Business Wire | Press release

Share
ADVA unveils market’s first high-performance optical cesium clock

ADVA (FSE: ADV) today achieved an industry first with the introduction of its Oscilloquartz high-performance optical cesium atomic clock. The coreSync OSA 3300-HP is ADVA’s latest innovation in assured PNT, ushering in a new age of precise synchronization with unprecedented stability. Following ADVA’s launch of the first optical pumping timing solution two years ago, the OSA 3350 ePRC+, the OSA 3300-HP takes the technology to new levels. It has a 10-year lifetime compared to the five years offered by currently available high-performance magnetic clocks. As the market’s only high-performance optical cesium clock, the OSA 3300-HP sets a new benchmark for precision and availability, providing the resilience required for PNT assurance in critical infrastructure and empowering service providers to deliver differentiated SLA timing offerings with integrated GNSS backup. The feature-rich device has embedded Ethernet- and IP-based management as well as a user-friendly touchscreen GUI.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220629005667/en/

“The launch of our coreSync OSA 3300-HP marks a key milestone in the design of atomic frequency and phase standards. After many years of extensive work in our Swiss laboratories supported by the European Space Agency, we now have a mature, state-of-the-art technology that enables a major leap in the accuracy and stability of network timing while providing a substantially longer lifetime,” said Gil Biran, GM of Oscilloquartz, ADVA. ”From 5G mobile services to mission-critical defense applications, our OSA 3300-HP will be a truly disruptive enhancement of our aPNT+ technology. And what makes its arrival so significant is that it comes at a moment when existing synchronization solutions in fixed, wireless and cable networks are being stretched to the limit, while the threat of GNSS cyberattacks also continues to grow. Across a wide range of industries, our high-performance cesium atomic clock will meet new timing demands, create new value and open up new possibilities for PNT assurance in critical infrastructure.”

Atomic clocks offer the ultimate synchronization backup for networks that rely on GNSS-based timing, combining high accuracy with outstanding availability. Offering performance that far exceeds best-in-class magnetic cesium devices, the OSA 3300-HP is the industry’s first commercial high-performance optical cesium atomic clock. Featuring an all-digital design, it leverages optical-pumping techniques using laser diodes. This enables it to measure 100 times the number of atoms, making it radically more efficient compared to existing primary reference clock (PRC) technologies. Its product lifespan is 100% longer than competing high-performance magnetic cesium clocks; the OSA 3300-HP delivers optimum stability for over 10 years. What’s more, further to the launch of the OSA 3300-HP, ADVA is also announcing a dual-purpose enhancement of its OSA 3350 ePRC+. Now, as well as providing phase holdover as part of ePRTC systems, it can be utilized as a free-running frequency source with enhanced standard performance.

“What we’ve accomplished with our optical cesium atomic clock solutions is more than incremental innovation. Industrializing optical pumping techniques was widely considered to be impossible. But that’s what our team has achieved. Now, we’re taking precision timing to the next level, empowering networks with nanosecond accuracy and phenomenal stability,” commented Patrick Berthoud, time and frequency chief scientist at Oscilloquartz, ADVA. “As well as meeting new sync requirements, our OSA 3300-HP will help simplify operations with its easy-to-use GUI for intuitive configuration and operation. These devices will support advances in a host of different technology fields. Able to meet the most demanding applications in data centers, financial networks, smart grids, transportation, metrology, scientific research and more, they will also be a foundation for future innovation as we continue to expand the boundaries of possibility for accuracy and stability.”

Learn more about ADVA’s OSA 3300-HP in these slides: https://adva.li/osa-3300-hp-slides .

About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .

About Oscilloquartz
Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we’re creating new opportunities for tomorrow’s networks. For more information, please visit us at www.oscilloquartz.com .

Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com

Social Media:

https://www.facebook.com/ADVAOpticalNetworking

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release

The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t

Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release

The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a

SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release

Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye